This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
July 28, 2011 /PRNewswire/ -- A study published by ITG this week revealed that U.S. oncologists expect Amgen's (NASDAQ: AMGN) recently approved
XGEVA (denosumab) to become the top-prescribed drug over the next year for the prevention of skeletal-related events (SREs) in prostate cancer patients. Furthermore, although Novartis' (NYSE: NVS)
Zometa (zoledronic acid) will likely remain the top-prescribed drug for preventing SREs in breast and lung cancer patients, physicians in the study believe
XGEVA's share will more than double for these indications over the next 12 months.
Zometa maintains a dominant position in preventing skeletal-related events in prostate, breast, and lung cancer patients, but our data clearly show that
XGEVA has already obtained significant penetration in the market. Assuming physicians and patients continue to be happy with
XGEVA, the product is on track to meet pre-launch expectations and become the top-prescribed drug in this class within the next few years," said
Hannah Slater, lead researcher on the study.
The report, entitled
Event Pulse: Launch of XGEVA, explores how the launch of Amgen's
XGEVA is transforming prescribing U.S. physician practices in preventing and treating SREs in cancer patients with solid tumors. The study shows that physicians in ITG's Oncology Panel are already prescribing
XGEVA for more than 10% of their prostate, breast, and lung cancer patients who have bone metastases. Physicians in the panel did acknowledge
XGEVA's relatively high cost and also expressed concerns about risks associated with osteonecrosis of the jaw, but they generally expressed enthusiasm for
XGEVA's increased efficacy, its subcutaneous route of administration, and its convenient dosing. Not only do they plan to initiate more patients on
XGEVA as a first-line therapy, physicians also expect to switch a significant number of patients from
XGEVA over the next year.
Amgen's denosumab first received approval for the treatment of osteoporosis in
June 2010 under the trade name,
Prolia, and it received approval for a second indication in
November 2010 under the trade name,
XGEVA, for the prevention of SREs in patients with bone metastases from solid tumors. Amgen has since submitted a supplemental Biologics License Application (sBLA) to the FDA to further expand the indication for
XGEVA to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved,
XGEVA would be the first therapy licensed to prevent or delay the spread of cancer to the bone.
Event Pulse: Launch of XGEVA includes analysis of a targeted survey of 50 oncologists and 50 urologists, and 10 in-depth telephone interviews with pharmacy directors at major managed care organizations. Conducted from June to
July 2011, the report provides an in-depth look at how the launch of
XGEVA will impact the treatment paradigm among competing agents in the prevention of SREs in the prostate, breast, and lung cancer markets. The study also examines the reimbursement climate for existing and anticipated SRE-prevention therapies.
About Event PulseEvent Pulse is a syndicated report series that evaluates the impact of market events on physician treatment practices. These report series provide information on how changes such as new products, data, or guidelines fit into the treatment algorithm, impact current therapies and change market dynamics.
About ITG Majestic Market Research
ITG's Majestic Market Research is the primary market research offering of ITG (NYSE: ITG), an independent agency brokerage firm founded in 1987. Since 2002, ITG has revolutionized the research business with its differentiated research platform based upon leveraging large amounts of statistically relevant, real-time data.